---
title: Reducing targeting noise by supplementing claims with oncology labs
description: See how our client uses HealthVerity eXOs to answer early RWE questions faster with credible, decision-ready insights.
image: https://info.healthverity.com/hubfs/reducing-targeting-noise-by-supplementing-claims-with-oncology-labs-2.png
---

- [Contact](https://healthverity.com/contact/)
- [Sign In](https://marketplace.healthverity.com/)

[![HealthVerity](https://info.healthverity.com/hs-fs/hubfs/raw_assets/public/Healthverity_May2023/images/healthverity-2023-logo2x.png?width=300&height=58&name=healthverity-2023-logo2x.png "HealthVerity")](https://healthverity.com/)

- How We Help 
    - New Products 
          - [HealthVerity TAXONOMY](https://healthverity.com/taxonomy-portal/)
          - [Precision Event Alerts](https://healthverity.com/precision-event-alerts/)
    - HealthVerity Marketplace 
          - [Overview](https://healthverity.com/marketplace/)
          - [HealthVerity Marketplace](https://healthverity.com/marketplace/healthverity-marketplace/)
          - [Data Ecosystem](https://healthverity.com/marketplace/data-ecosystem/)
          - [Media Measurement](https://healthverity.com/media-measurement/)
          - [Insurance Underwriting](https://healthverity.com/insurance-underwriting/)
    - HealthVerity Mastersets 
          - [Overview](https://healthverity.com/mastersets/)
          - [Maternal Outcomes Masterset](https://healthverity.com/mastersets/mom/)
          - [Chronic Kidney Disease Masterset](https://healthverity.com/mastersets/chronic-kidney-disease/)
          - [Mortality Masterset](https://healthverity.com/mastersets/mortality/)
          - [COVID-19 Masterset](https://healthverity.com/mastersets/covid-19/)
    - HealthVerity FLOW 
          - [Overview](https://healthverity.com/flow/)
          - [HealthVerity FLOW for Clinical Trials](https://healthverity.com/flow/clinical-trials/)
          - [HealthVerity FLOW for Commercial](https://healthverity.com/flow/commercial/)
          - [HealthVerity FLOW for Registries](https://healthverity.com/flow/registries/)
          - [Identity Manager](https://healthverity.com/identity-manager/)
          - [Governance Manager](https://healthverity.com/governance-manager/)
          - [Smart Contracts Manager](https://healthverity.com/smart-contracts-manager/)
          - [Audience Manager](https://healthverity.com/audience-manager/)
- Who We Serve 
    - [Life Sciences](https://healthverity.com/life-sciences/)
    - [Government](https://healthverity.com/government/)
    - [Insurance](https://healthverity.com/insurance/)
    - [Channel Partners](https://healthverity.com/channel-partners/)
    - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/)
- Resources 
    - [HealthVerity Blog](https://blog.healthverity.com/)
    - [News & Events](https://healthverity.com/resources/news-and-events/)
    - [Resource Library](https://healthverity.com/resources/resource-library/)
    - [Publications](https://healthverity.com/resources/publications/)
    - [The IPGE Approach](https://healthverity.com/ipge-approach/)
- [Careers](https://healthverity.com/careers/)
- [About Us](https://healthverity.com/about-us/)

![reducing-targeting-noise-by-supplementing-claims-with-oncology-labs-1](https://info.healthverity.com/hs-fs/hubfs/reducing-targeting-noise-by-supplementing-claims-with-oncology-labs-1.png?width=813&height=301&name=reducing-targeting-noise-by-supplementing-claims-with-oncology-labs-1.png)

###### CASE STUDY

# Reducing targeting noise by supplementing claims with oncology labs: Metastatic breast cancer case study

In precision oncology, a diagnosis code can point you in the right direction, but it rarely tells the whole story. This case study shows how supplementing claims with oncology lab results can help you  reduce targeting noise and engage the right providers sooner.

### What you'll learn:

- Why claims-only targeting can create outsized provider lists when therapy eligibility depends on biomarker-defined subtypes
- How syncing longitudinal claims with genomic lab results narrowed 75,395 metastatic breast cancer patients to 1,188 subtype-confirmed patients, and 9,168 oncologists to 340 actionable targets
- Why genomic testing can create a critical window for field engagement before treatment decisions are made

© 2026 HealthVerity, Inc.    |    [Terms & Conditions](https://healthverity.com/terms-and-conditions/)    |    [Privacy Policy](https://healthverity.com/privacy-policy/)

![](https://px.ads.linkedin.com/collect/?pid=4361946&fmt=gif)